Evidence map›Paper›PMID 36687467›Full record

ArticleNeurobiology of pain (Cambridge, Mass.)

Intramuscular injection of nerve growth factor as a model of temporomandibular disorder: nature, time-course, and sex differences characterising the pain experience.

S M Schabrun, E Si, S K Millard, A K I Chiang, S Chen, N S Chowdhury, D A Seminowicz

Open access · goldAbstract read
In one paragraph

Article in Neurobiology of pain (Cambridge, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. A novel cortical biomarker signature predicts individual pain sensitivity.medRxiv : the preprint server for health sciences · 2024
    Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

S M SchabrunCenter for Pain IMPACT, Neuroscience Research Australia, Sydney, New South Wales, Australia.
E SiCenter for Pain IMPACT, Neuroscience Research Australia, Sydney, New South Wales, Australia.
S K MillardCenter for Pain IMPACT, Neuroscience Research Australia, Sydney, New South Wales, Australia.
A K I ChiangCenter for Pain IMPACT, Neuroscience Research Australia, Sydney, New South Wales, Australia.
S ChenDepartment of Neural and Pain Sciences, University of Maryland School of Dentistry, Baltimore, MD, USA.
N S ChowdhuryCenter for Pain IMPACT, Neuroscience Research Australia, Sydney, New South Wales, Australia.
D A SeminowiczCenter for Pain IMPACT, Neuroscience Research Australia, Sydney, New South Wales, Australia.
Neuroscience Research Australia · AUUniversity of Maryland, Baltimore · USUNSW Sydney · AUWestern University · CA

Funding

Validation of a novel cortical biomarker signature for painR61NS113269 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI DA SILVA, JOYCE TEIXEIRA, SCHABRUN, SIOBHAN · 2019 to 2019
$1.4M
NINDS NIH HHS R61 NS113269
6 · The paper itself

Abstract

Background: Temporomandibular disorder (TMD) is a common condition that frequently transitions to chronic symptoms. Experimental pain models that mimic the symptoms of clinical TMD may be useful in understanding the mechanisms, and sex differences, present in this disorder. Here we aimed to comprehensively characterise the nature and time-course of pain, functional impairment and hyperalgesia induced by repeated intramuscular injection of nerve growth factor (NGF) into the masseter muscle, and to investigate sex differences in the NGF-induced pain experience. Methods: 94 healthy individuals participated in a longitudinal study with 30-day follow-up. NGF was injected into the right masseter muscle on Day 0 and Day 2. Participants attended laboratory sessions to assess pain (Numerical Rating Scale; NRS), functional limitation (mouth opening distance, Jaw Functional Limitation Scale; JFLS) and mechanical sensitization (pressure pain thresholds; PPTs) on Days 0, 2 and 5 and completed twice daily electronic pain dairies from Day 0 to day 30. Results: Peak pain averaged 2.0/10 (95 % CI: 1.6-2.4) at rest and 4.3/10 (95 % CI: 3.9-4.8) on chewing. Pain-free mouth opening distance reduced from 5.0 cm (95 % CI: 4.8-5.1 cm) on Day 0 to 3.7 cm (95 % CI: 3.5-3.9 cm) on Day 5. The greatest reduction in PPTs was observed over the masseter muscle. Females experienced higher pain, greater functional impairment, and greater sensitivity to mechanical stimuli than males. Conclusion: Intramuscular injection of NGF is a useful model with which to explore the mechanisms, and sex differences, present in clinical TMD.

Indexed as

Nerve growth factorOrofacial painPain durationPain intensitySex differences

Identifiers

PMID36687467
PMCPMC9852786
OpenAlexW4315864835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.